Israel’s BrainStorm (reported here previously) reported promising results of pre-clinical trials for its Nurown treatment for Acute Respiratory Distress Syndrome (ARDS) brought about by Covid-19. The NurOwn cells reduced the cytokine storm and lung damage. https://ir.brainstorm-cell.com/2020-07-23-BrainStorm-Announces-Groundbreaking-Pre-Clinical-Study-of-NurOwn-R-derived-Exosome-Based-Treatment-for-COVID-19-ARDS

As reported (here) previously, the stem cell treatment for ALS from Israel’s Brainstorm is doing well in trials.  The latest Phase 2 trial of Brainstorm’s autologous bone-marrow derived MSC-NTF cells (Nurown) in 48 patients at 3 US sites was effective … Continue reading →

Israel’s BrainStorm has received FDA approval to use its Nurown stem cells in a Phase 2 trial for the treatment of Multiple Sclerosis (MS). MS affects approximately 1 million individuals in the U.S. and 2.5 million individuals worldwide.  Nurown is … Continue reading →

Israel’s Brainstorm has announced positive final results from its phase 2a clinical trial of NurOwn cells in amyotrophic lateral sclerosis (ALS) patients used on 14 subjects at Hadassah Medical Center in Jerusalem.  Nearly all subjects experienced clinical benefit. http://www.brainstorm-cell.com/index.php/news-events/331-january-5-2015

The US FDA has designated NurOwn, developed by Israel’s Brainstorm, as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s Disease). http://jewishbusinessnews.com/2014/10/08/brainstorms-stem-cell-based-drug-nurown-gets-fda-fast-track-approval/

Israel’s BrainStorm reported positive interim results of Phase IIa ALS trials of its “NurOwn” stem cell therapy. 71% of patients were in decline before treatment but after treatment 63% were either stabilized or had improved neurological function. http://www.brainstorm-cell.com/index.php/news-a-events/302-june-2-2014

Israeli biotech Brainstorm has received a US patent for its autologous stem cell technology for the treatment of neuro-degenerative diseases. Brainstorm is preparing for its US upcoming multi-center Phase II trial with its proprietary NurOwn stem cell therapy. http://www.brainstorm-cell.com/index.php/news-a-events/291-march-24-2014

(Thanks to NoCamels) ALS (Lou Gehrig’s) sufferer Rabbi Refael Shmulevitz had been given two to four years to live. He lost the ability to talk clearly and was confined to a wheelchair. Following Brainstorm‘s ‘NurOwn’ stem cell treatment he can … Continue reading →